Percutaneous ultrasonography-guided permanent iodine-125 implantation as salvage therapy for recurrent head and neck carcimonas
Twenty-nine (29) patients with recurrent head and neck carcinomas underwent (125)I seed permanent implantation under ultrasonography guidance and the feasibility and efficacy of (125)I seed implantation were assessed. The postplan evaluation showed that the actuarial D90 of (125)I seeds ranged from...
Gespeichert in:
| Veröffentlicht in: | Cancer biotherapy & radiopharmaceuticals 2011-12, Vol.26 (6), p.753-757 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 757 |
|---|---|
| container_issue | 6 |
| container_start_page | 753 |
| container_title | Cancer biotherapy & radiopharmaceuticals |
| container_volume | 26 |
| creator | Jiang, Ping Jiang, Yuliang Wang, Jun-jie Meng, Na Ran, Weiqiang Qu, Ang Yang, Ruijie |
| description | Twenty-nine (29) patients with recurrent head and neck carcinomas underwent (125)I seed permanent implantation under ultrasonography guidance and the feasibility and efficacy of (125)I seed implantation were assessed. The postplan evaluation showed that the actuarial D90 of (125)I seeds ranged from 90 to 160 Gy (median, 130 Gy). The activity of each (125)I seed ranged from 0.35 to 0.8 mCi (median, 0.6 mCi). The total number of sources implanted ranged from 3 to 61 (median, 22). The follow-up ranged from 3 to 40 months (median, 8 months). The 1-, 2-, and 3-year local control rates were 53.1%, 34.8%, and 17.4%, respectively, with a median local control of 16 months (95% confidence interval, 5.8-26.1). The 1-, 2-, and 3- year survival rates were 54.1%, 27.5%, and 27.5%, respectively (median, 13 months; 95% confidence interval, 6.0-19.9). Of the 25 patients, 5 (17.2%) died of local recurrence and 7 (24.1%) died of metastases; 2 patients showed recurrences at 3 and 8 months after seed implantation and subsequently died of pneumonia. One (1) patient died of heart disease. One (1) developed ulceration with tumor progression. Blood vessel damage and neuropathy were not observed. Percutaneous ultrasound-guided (125)I seed implantation is a feasible, safe salvage for patients with recurrent carcinomas of the head and neck. |
| doi_str_mv | 10.1089/cbr.2010.0844 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_920802907</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>920802907</sourcerecordid><originalsourceid>FETCH-LOGICAL-c351t-ad6df8a95ecbf708759e5b811175794891cb302ac526422d6e1eb10174466d283</originalsourceid><addsrcrecordid>eNqFkTuP1TAQRi0EYpeFkhZZNFRZxk4c2yVaLQ9pJSigjib25N4siR3sBOlW_HUc3YWChmoeOjPSp8PYSwHXAox96_p0LaFMYJrmEbsUSunKGCUfl77sKquNumDPcr4HgBZa_ZRdSCnqGqy9ZL--UHLbioHilvk2rQlzDPGQcDmeqsM2evJ8oTQXIqx8jH4MVAmp-DgvE4YV1zEGjplnnH7igfh6pHJ84kNMPJHbUtoPj4SeY_A8kPvOHSY3zjFgfs6eDDhlevFQr9i397dfbz5Wd58_fLp5d1e5Wom1Qt_6waBV5PpBg9HKkuqNEEIrbRtjhetrkOiUbBspfUuCegFCN03bemnqK_bm_HdJ8cdGee3mMTuapnPyzkowIC3o_5Ngtaql2MnX_5D3cUuhxCiQaaEWQhWoOkMuxZwTDd2SxhnTqRPQ7Qa7YrDbDXa7wcK_eni69TP5v_QfZfVv8AyXnQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>908603115</pqid></control><display><type>article</type><title>Percutaneous ultrasonography-guided permanent iodine-125 implantation as salvage therapy for recurrent head and neck carcimonas</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>Jiang, Ping ; Jiang, Yuliang ; Wang, Jun-jie ; Meng, Na ; Ran, Weiqiang ; Qu, Ang ; Yang, Ruijie</creator><creatorcontrib>Jiang, Ping ; Jiang, Yuliang ; Wang, Jun-jie ; Meng, Na ; Ran, Weiqiang ; Qu, Ang ; Yang, Ruijie</creatorcontrib><description>Twenty-nine (29) patients with recurrent head and neck carcinomas underwent (125)I seed permanent implantation under ultrasonography guidance and the feasibility and efficacy of (125)I seed implantation were assessed. The postplan evaluation showed that the actuarial D90 of (125)I seeds ranged from 90 to 160 Gy (median, 130 Gy). The activity of each (125)I seed ranged from 0.35 to 0.8 mCi (median, 0.6 mCi). The total number of sources implanted ranged from 3 to 61 (median, 22). The follow-up ranged from 3 to 40 months (median, 8 months). The 1-, 2-, and 3-year local control rates were 53.1%, 34.8%, and 17.4%, respectively, with a median local control of 16 months (95% confidence interval, 5.8-26.1). The 1-, 2-, and 3- year survival rates were 54.1%, 27.5%, and 27.5%, respectively (median, 13 months; 95% confidence interval, 6.0-19.9). Of the 25 patients, 5 (17.2%) died of local recurrence and 7 (24.1%) died of metastases; 2 patients showed recurrences at 3 and 8 months after seed implantation and subsequently died of pneumonia. One (1) patient died of heart disease. One (1) developed ulceration with tumor progression. Blood vessel damage and neuropathy were not observed. Percutaneous ultrasound-guided (125)I seed implantation is a feasible, safe salvage for patients with recurrent carcinomas of the head and neck.</description><identifier>ISSN: 1084-9785</identifier><identifier>EISSN: 1557-8852</identifier><identifier>DOI: 10.1089/cbr.2010.0844</identifier><identifier>PMID: 22133099</identifier><language>eng</language><publisher>United States: Mary Ann Liebert, Inc</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Brachytherapy - methods ; Carcinoma, Squamous Cell - diagnostic imaging ; Carcinoma, Squamous Cell - radiotherapy ; Female ; Follow-Up Studies ; Head and Neck Neoplasms - diagnostic imaging ; Head and Neck Neoplasms - radiotherapy ; Humans ; Iodine Radioisotopes - administration & dosage ; Male ; Middle Aged ; Neoplasm Recurrence, Local - diagnostic imaging ; Neoplasm Recurrence, Local - radiotherapy ; Retrospective Studies ; Salvage Therapy - adverse effects ; Salvage Therapy - methods ; Squamous Cell Carcinoma of Head and Neck ; Survival Rate ; Ultrasonography - methods</subject><ispartof>Cancer biotherapy & radiopharmaceuticals, 2011-12, Vol.26 (6), p.753-757</ispartof><rights>(©) Copyright 2011, Mary Ann Liebert, Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c351t-ad6df8a95ecbf708759e5b811175794891cb302ac526422d6e1eb10174466d283</citedby><cites>FETCH-LOGICAL-c351t-ad6df8a95ecbf708759e5b811175794891cb302ac526422d6e1eb10174466d283</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22133099$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Jiang, Ping</creatorcontrib><creatorcontrib>Jiang, Yuliang</creatorcontrib><creatorcontrib>Wang, Jun-jie</creatorcontrib><creatorcontrib>Meng, Na</creatorcontrib><creatorcontrib>Ran, Weiqiang</creatorcontrib><creatorcontrib>Qu, Ang</creatorcontrib><creatorcontrib>Yang, Ruijie</creatorcontrib><title>Percutaneous ultrasonography-guided permanent iodine-125 implantation as salvage therapy for recurrent head and neck carcimonas</title><title>Cancer biotherapy & radiopharmaceuticals</title><addtitle>Cancer Biother Radiopharm</addtitle><description>Twenty-nine (29) patients with recurrent head and neck carcinomas underwent (125)I seed permanent implantation under ultrasonography guidance and the feasibility and efficacy of (125)I seed implantation were assessed. The postplan evaluation showed that the actuarial D90 of (125)I seeds ranged from 90 to 160 Gy (median, 130 Gy). The activity of each (125)I seed ranged from 0.35 to 0.8 mCi (median, 0.6 mCi). The total number of sources implanted ranged from 3 to 61 (median, 22). The follow-up ranged from 3 to 40 months (median, 8 months). The 1-, 2-, and 3-year local control rates were 53.1%, 34.8%, and 17.4%, respectively, with a median local control of 16 months (95% confidence interval, 5.8-26.1). The 1-, 2-, and 3- year survival rates were 54.1%, 27.5%, and 27.5%, respectively (median, 13 months; 95% confidence interval, 6.0-19.9). Of the 25 patients, 5 (17.2%) died of local recurrence and 7 (24.1%) died of metastases; 2 patients showed recurrences at 3 and 8 months after seed implantation and subsequently died of pneumonia. One (1) patient died of heart disease. One (1) developed ulceration with tumor progression. Blood vessel damage and neuropathy were not observed. Percutaneous ultrasound-guided (125)I seed implantation is a feasible, safe salvage for patients with recurrent carcinomas of the head and neck.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Brachytherapy - methods</subject><subject>Carcinoma, Squamous Cell - diagnostic imaging</subject><subject>Carcinoma, Squamous Cell - radiotherapy</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Head and Neck Neoplasms - diagnostic imaging</subject><subject>Head and Neck Neoplasms - radiotherapy</subject><subject>Humans</subject><subject>Iodine Radioisotopes - administration & dosage</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Neoplasm Recurrence, Local - diagnostic imaging</subject><subject>Neoplasm Recurrence, Local - radiotherapy</subject><subject>Retrospective Studies</subject><subject>Salvage Therapy - adverse effects</subject><subject>Salvage Therapy - methods</subject><subject>Squamous Cell Carcinoma of Head and Neck</subject><subject>Survival Rate</subject><subject>Ultrasonography - methods</subject><issn>1084-9785</issn><issn>1557-8852</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNqFkTuP1TAQRi0EYpeFkhZZNFRZxk4c2yVaLQ9pJSigjib25N4siR3sBOlW_HUc3YWChmoeOjPSp8PYSwHXAox96_p0LaFMYJrmEbsUSunKGCUfl77sKquNumDPcr4HgBZa_ZRdSCnqGqy9ZL--UHLbioHilvk2rQlzDPGQcDmeqsM2evJ8oTQXIqx8jH4MVAmp-DgvE4YV1zEGjplnnH7igfh6pHJ84kNMPJHbUtoPj4SeY_A8kPvOHSY3zjFgfs6eDDhlevFQr9i397dfbz5Wd58_fLp5d1e5Wom1Qt_6waBV5PpBg9HKkuqNEEIrbRtjhetrkOiUbBspfUuCegFCN03bemnqK_bm_HdJ8cdGee3mMTuapnPyzkowIC3o_5Ngtaql2MnX_5D3cUuhxCiQaaEWQhWoOkMuxZwTDd2SxhnTqRPQ7Qa7YrDbDXa7wcK_eni69TP5v_QfZfVv8AyXnQ</recordid><startdate>201112</startdate><enddate>201112</enddate><creator>Jiang, Ping</creator><creator>Jiang, Yuliang</creator><creator>Wang, Jun-jie</creator><creator>Meng, Na</creator><creator>Ran, Weiqiang</creator><creator>Qu, Ang</creator><creator>Yang, Ruijie</creator><general>Mary Ann Liebert, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QP</scope><scope>7T5</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88A</scope><scope>88E</scope><scope>88I</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>7QO</scope><scope>8FD</scope><scope>FR3</scope><scope>P64</scope></search><sort><creationdate>201112</creationdate><title>Percutaneous ultrasonography-guided permanent iodine-125 implantation as salvage therapy for recurrent head and neck carcimonas</title><author>Jiang, Ping ; Jiang, Yuliang ; Wang, Jun-jie ; Meng, Na ; Ran, Weiqiang ; Qu, Ang ; Yang, Ruijie</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c351t-ad6df8a95ecbf708759e5b811175794891cb302ac526422d6e1eb10174466d283</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Brachytherapy - methods</topic><topic>Carcinoma, Squamous Cell - diagnostic imaging</topic><topic>Carcinoma, Squamous Cell - radiotherapy</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Head and Neck Neoplasms - diagnostic imaging</topic><topic>Head and Neck Neoplasms - radiotherapy</topic><topic>Humans</topic><topic>Iodine Radioisotopes - administration & dosage</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Neoplasm Recurrence, Local - diagnostic imaging</topic><topic>Neoplasm Recurrence, Local - radiotherapy</topic><topic>Retrospective Studies</topic><topic>Salvage Therapy - adverse effects</topic><topic>Salvage Therapy - methods</topic><topic>Squamous Cell Carcinoma of Head and Neck</topic><topic>Survival Rate</topic><topic>Ultrasonography - methods</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Jiang, Ping</creatorcontrib><creatorcontrib>Jiang, Yuliang</creatorcontrib><creatorcontrib>Wang, Jun-jie</creatorcontrib><creatorcontrib>Meng, Na</creatorcontrib><creatorcontrib>Ran, Weiqiang</creatorcontrib><creatorcontrib>Qu, Ang</creatorcontrib><creatorcontrib>Yang, Ruijie</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>Biotechnology Research Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><jtitle>Cancer biotherapy & radiopharmaceuticals</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Jiang, Ping</au><au>Jiang, Yuliang</au><au>Wang, Jun-jie</au><au>Meng, Na</au><au>Ran, Weiqiang</au><au>Qu, Ang</au><au>Yang, Ruijie</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Percutaneous ultrasonography-guided permanent iodine-125 implantation as salvage therapy for recurrent head and neck carcimonas</atitle><jtitle>Cancer biotherapy & radiopharmaceuticals</jtitle><addtitle>Cancer Biother Radiopharm</addtitle><date>2011-12</date><risdate>2011</risdate><volume>26</volume><issue>6</issue><spage>753</spage><epage>757</epage><pages>753-757</pages><issn>1084-9785</issn><eissn>1557-8852</eissn><abstract>Twenty-nine (29) patients with recurrent head and neck carcinomas underwent (125)I seed permanent implantation under ultrasonography guidance and the feasibility and efficacy of (125)I seed implantation were assessed. The postplan evaluation showed that the actuarial D90 of (125)I seeds ranged from 90 to 160 Gy (median, 130 Gy). The activity of each (125)I seed ranged from 0.35 to 0.8 mCi (median, 0.6 mCi). The total number of sources implanted ranged from 3 to 61 (median, 22). The follow-up ranged from 3 to 40 months (median, 8 months). The 1-, 2-, and 3-year local control rates were 53.1%, 34.8%, and 17.4%, respectively, with a median local control of 16 months (95% confidence interval, 5.8-26.1). The 1-, 2-, and 3- year survival rates were 54.1%, 27.5%, and 27.5%, respectively (median, 13 months; 95% confidence interval, 6.0-19.9). Of the 25 patients, 5 (17.2%) died of local recurrence and 7 (24.1%) died of metastases; 2 patients showed recurrences at 3 and 8 months after seed implantation and subsequently died of pneumonia. One (1) patient died of heart disease. One (1) developed ulceration with tumor progression. Blood vessel damage and neuropathy were not observed. Percutaneous ultrasound-guided (125)I seed implantation is a feasible, safe salvage for patients with recurrent carcinomas of the head and neck.</abstract><cop>United States</cop><pub>Mary Ann Liebert, Inc</pub><pmid>22133099</pmid><doi>10.1089/cbr.2010.0844</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1084-9785 |
| ispartof | Cancer biotherapy & radiopharmaceuticals, 2011-12, Vol.26 (6), p.753-757 |
| issn | 1084-9785 1557-8852 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_920802907 |
| source | MEDLINE; Alma/SFX Local Collection |
| subjects | Adult Aged Aged, 80 and over Brachytherapy - methods Carcinoma, Squamous Cell - diagnostic imaging Carcinoma, Squamous Cell - radiotherapy Female Follow-Up Studies Head and Neck Neoplasms - diagnostic imaging Head and Neck Neoplasms - radiotherapy Humans Iodine Radioisotopes - administration & dosage Male Middle Aged Neoplasm Recurrence, Local - diagnostic imaging Neoplasm Recurrence, Local - radiotherapy Retrospective Studies Salvage Therapy - adverse effects Salvage Therapy - methods Squamous Cell Carcinoma of Head and Neck Survival Rate Ultrasonography - methods |
| title | Percutaneous ultrasonography-guided permanent iodine-125 implantation as salvage therapy for recurrent head and neck carcimonas |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-26T08%3A34%3A22IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Percutaneous%20ultrasonography-guided%20permanent%20iodine-125%20implantation%20as%20salvage%20therapy%20for%20recurrent%20head%20and%20neck%20carcimonas&rft.jtitle=Cancer%20biotherapy%20&%20radiopharmaceuticals&rft.au=Jiang,%20Ping&rft.date=2011-12&rft.volume=26&rft.issue=6&rft.spage=753&rft.epage=757&rft.pages=753-757&rft.issn=1084-9785&rft.eissn=1557-8852&rft_id=info:doi/10.1089/cbr.2010.0844&rft_dat=%3Cproquest_cross%3E920802907%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=908603115&rft_id=info:pmid/22133099&rfr_iscdi=true |